REG - EKF Diagnostics Hldg - Posting of Annual Report & Notice of AGM

EKF Diagnostics HoldingsAnnouncement

21/04/2023 14:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230421:nRSU1048Xa&default-theme=true

RNS Number : 1048X  EKF Diagnostics Holdings PLC  21 April 2023

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Posting of Annual Report & Accounts
And
Notice of AGM

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, confirms that the Annual Report and Accounts for the year ended 31
December 2022 ("2022 Annual Report") and the Notice of the 2023 Annual General
Meeting ("AGM") have now been published on the Company's website:

https://www.ekfdiagnostics.com/documents-reports.html
(https://www.ekfdiagnostics.com/documents-reports.html)

 

The 2022 Annual Report, the Notice of AGM and details for voting by
proxy will be posted today to shareholders who have not consented to receive
electronic communications.

 

The AGM is to be held at 10:30 am on 17 May 2023 at 6 Stratton Street
Mayfair, London W1J 8LD and will consider the Resolutions set out in the
Notice of AGM.

 

The Company is providing a facility for shareholders to listen in to the AGM
either online or telephonically (in a non-voting capacity) and there will be
an opportunity for shareholders to ask questions. In order to facilitate the
process, the Directors would request that shareholders register for the
meeting and submit questions in advance, before 10:30 am on 15 May 2023. To
register for dial-in details and to submit any questions please contact
Walbrook PR via email at ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)  or
call +44 (0)20 7933 8780.

 

Proxy voting

Shareholders will not receive a hard copy form of proxy for the 2023 AGM in
the post. Instead, shareholders will be able to vote electronically using the
link available via https://www.signalshares.com
(https://www.signalshares.com) and selecting the "Proxy Voting" link or
lodging a proxy appointment by using the CREST Proxy Voting Service.

 

Alternatively, shareholders may request a hard copy form of proxy directly
from the Registrars, Link Group, on Tel: 0371 664 0391. Calls are charged at
the standard geographic rate and will vary by provider. Calls outside the
United Kingdom will be charged at the applicable international rate. Lines are
open between 09:00 - 17:30, Monday to Friday excluding public holidays in
England and Wales.

 

 EKF Diagnostics Holdings plc                                 www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair / Marc Davies, CFO             Tel: +44 (0)29 2071 0570

 Singer Capital Markets (Nominated Adviser & Broker)                                        Tel: +44 (0)20 7496 3000
 Aubrey Powell / George Tzimas / Oliver Platts

 Walbrook PR Limited               Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Lianne Applegarth  Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

·    Point-of-Care analysers in the key areas of Hematology and Diabetes,
as well as Central Laboratory products including clinical chemistry reagents,
analysers and centrifuges

 

·    Life Sciences services provide specialist manufacture of enzymes and
custom products for use in diagnostic food and industrial applications, as
well as other higher value Contract Manufacturing services

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCIBMJTMTTTBIJ